

Table S1. Results from two-sample Mendelian Randomisation analyses of associations between inflammatory markers and inflammatory conditions (Polycystic ovary syndrome and Endometriosis)

Outcome:		Polycystic ovary syndrome					Endometriosis				
Exposure	SNPs	IVW	MRE	WMe	WMo	SMo	IVW	MRE	WMe	WMo	SMo
IL-1 β	3	1.10 (0.67, 1.83)	1.86 (0.27, 12.99)	1.11 (0.62, 1.98)	1.24 (0.71, 2.17)	0.70 (0.29, 1.69)	0.95 (0.81, 1.11)	1.45 (0.80, 2.64)	0.97 (0.81, 1.17)	0.98 (0.81, 1.19)	1.01 (0.79, 1.30)
IL-2	5	0.99 (0.61, 1.64)	1.03 (0.37, 2.91)	0.96 (0.59, 1.56)	1.39 (0.71, 2.72)	0.71 (0.29, 1.75)	1.08 (0.88, 1.32)	1.34 (0.99, 1.81)	1.18 (1.01, 1.37)	1.19 (1.01, 1.40)	1.20 (1.02, 1.42)
IL-4	5	0.67 (0.35, 1.27)	0.73 (0.18, 2.93)	0.93 (0.40, 2.16)	1.01 (0.33, 3.05)	1.01 (0.33, 3.04)	1.07 (0.82, 1.39)	0.76 (0.51, 1.12)	1.12 (0.84, 1.49)	1.14 (0.76, 1.72)	1.13 (0.73, 1.75)
IL-5	5	0.73 (0.50, 1.08)	0.60 (0.24, 1.50)	0.82 (0.51, 1.33)	0.84 (0.44, 1.59)	0.83 (0.44, 1.57)	1.08 (0.95, 1.21)	1.09 (0.82, 1.44)	1.08 (0.94, 1.24)	1.09 (0.91, 1.31)	1.09 (0.91, 1.31)
IL-6	5	1.70 (0.94, 3.05)	1.67 (0.40 7.01)	1.63 (0.81, 3.31)	1.34 (0.50, 3.59)	1.25 (0.46, 3.37)	0.92 (0.72, 1.17)	0.96 (0.48, 1.90)	0.85 (0.65, 1.09)	0.75 (0.49, 1.15)	0.74 (0.51, 1.08)
IL-7	9	0.90 (0.67, 1.2)	0.85 (0.46, 1.56)	0.82 (0.56, 1.20)	0.77 (0.46, 1.29)	0.76 (0.47, 1.25)	1.02 (0.89, 1.17)	1.26 (0.99, 1.60)	1.02 (0.89, 1.18)	0.91 (0.67, 1.24)	0.95 (0.70, 1.29)
IL-8	4	0.97 (0.54, 1.75)	0.42 (0.10, 1.67)	0.89 (0.48, 1.65)	0.72 (0.27, 1.92)	0.70 (0.26, 1.91)	1.09 (0.94, 1.27)	1.24 (0.83, 1.84)	1.15 (0.97, 1.38)	1.16 (0.89, 1.51)	1.16 (0.90, 1.50)
IL-9	6	0.75 (0.47, 1.19)	1.50 (0.59, 3.83)	0.81 (0.47, 1.39)	0.79 (0.40, 1.58)	0.78 (0.34, 1.79)	1.15 (1.02, 1.30)	1.30 (0.98, 1.73)	1.16 (0.99, 1.37)	1.15 (0.94, 1.41)	1.18 (0.95, 1.46)
IL-10	10	0.73 (0.48, 1.12)	9.86 (0.21, 456.67)	0.79 (0.45, 1.39)	0.86 (0.37, 2.01)	0.88 (0.35, 2.18)	0.99 (0.87, 1.13)	0.72 (0.22, 2.34)	0.98 (0.83, 1.17)	0.96 (0.73, 1.25)	0.95 (0.73, 1.24)
IL-12	8	0.90 (0.48, 1.71)	1.86 (0.37, 9.33)	0.72 (0.37, 1.40)	0.71 (0.24, 2.14)	0.72 (0.22, 2.38)	0.98 (0.85, 1.14)	1.05 (0.72, 1.53)	0.96 (0.79, 1.17)	0.93 (0.70, 1.23)	0.95 (0.68, 1.31)
IL-13	7	1.00 (0.80, 1.24)	1.00 (0.66, 1.51)	0.98 (0.76, 1.26)	0.96 (0.73, 1.26)	1.26 (0.78, 2.04)	1.03 (0.96, 1.10)	1.03 (0.91, 1.17)	1.03 (0.95, 1.12)	1.03 (0.96, 1.12)	1.011 (0.88, 1.16)
IL-16	8	0.91 (0.57, 1.46)	0.89 (0.37, 2.13)	1.00 (0.72, 1.37)	1.01 (0.70, 1.45)	0.87 (0.43, 1.77)	0.94 (0.88, 1.02)	1.01 (0.89, 1.15)	0.95 (0.86, 1.04)	1.012 (0.91, 1.13)	0.87 (0.72, 1.05)
IL-17	8	1.01 (0.70, 1.53)	2.01 (0.87, 4.60)	1.05 (0.60, 1.83)	1.15 (0.55, 2.40)	1.04 (0.44, 2.46)	0.99 (0.87, 1.12)	0.98 (0.76, 1.27)	1.03 (0.87, 1.21)	1.04 (0.84, 1.28)	1.02 (0.78, 1.33)
IL-18	11	0.91 (0.73, 1.13)	0.95 (0.60, 1.51)	0.84 (0.63, 1.12)	0.85 (0.59, 1.24)	0.88 (0.55, 1.43)	1.00 (0.92, 1.09)	0.98 (0.82, 1.19)	0.96 (0.87, 1.06)	0.96 (0.83, 1.11)	1.15 (0.95, 1.40)
MCP-1/ CCL2	13	1.48 (1.10, 2.00)	1.61 (0.76, 3.41)	1.47 (0.99, 2.19)	1.47 (0.97, 2.23)	1.58 (0.81, 3.09)	0.98 (0.90, 1.08)	1.02 (0.81, 1.29)	1.06 (0.93, 1.21)	1.05 (0.91, 1.22)	0.95 (0.75, 1.20)
CRP	17	0.76 (0.51, 1.14)	1.12 (0.60, 2.12)	0.88 (0.55, 1.40)	0.89 (0.58, 1.37)	0.63 (0.23, 1.79)	1.01 (0.90, 1.13)	0.93 (0.78, 1.12)	1.09 (0.92, 1.28)	1.10 (0.93, 1.31)	1.16 (0.84, 1.60)
Interferon- γ	5	0.97 (0.33, 2.81)	0.72 (0.08, 6.53)	1.65 (0.76, 3.57)	1.97 (0.88, 4.40)	1.91 (0.90, 4.07)	0.99 (0.83, 1.17)	0.86 (0.63, 1.17)	0.97 (0.78, 1.22)	0.97 (0.73, 1.28)	1.00 (0.74, 1.35)
TNF- α	3	0.73 (0.38, 1.39)	0.43 (0.19, 0.96)	0.59 (0.31, 1.13)	0.55 (0.26, 1.20)	0.56 (0.24, 1.30)	1.06 (0.91, 1.24)	1.11 (0.86, 1.44)	1.08 (0.89, 1.30)	1.09 (0.87, 1.36)	1.09 (0.87, 1.36)

All data are reported as odds ratios (95% confidence interval), unless otherwise specified. Bold figures denote a statistically significant association with a p-value <0.05.

Abbreviations: CRP, c-reactive protein; IL, interleukin; IVW, Inverse variance weighted; MCP/CCL2, monocyte chemoattractant protein-1/ C-C motif chemokine ligand 2; MRE, Mendelian Randomisation-Egger; SNPs, single nucleotide polymorphisms; TNF- α , tumour necrosis factor- α ; WMe, weighted median; WMo, weighted mode.